In July 2018 the United States Food and Drug Administration (FDA) issued a final guidance document titled, “ANDA Submissions–Amendments to Abbreviated New Drug Applications under GDUFA–Guidance for Industry.” A guidance document represents the recommendations of the FDA, but is not legally binding. The Guidance Document explains how amendment submissions may affect an application’s review goal…